Basilar Artery Occlusion Chinese Endovascular Registry in Patients With Large-Core Infarct (BAOCHE-LC)

Endovascular Versus Medical Therapy for Acute Large-Core Basilar Artery Occlusion: A Multicenter Retrospective Registry Study (BAOCHE-LC)

This multicenter retrospective registry study evaluates the safety and effectiveness of endovascular therapy versus medical therapy for acute large-core basilar artery occlusion. It also investigates clinical, imaging, and laboratory factors associated with functional outcomes and mortality. Patients are grouped according to the treatment received in routine clinical practice.

Study Overview

• Status: Not yet recruiting
• Conditions: Ischemic Stroke; Basilar Artery Occlusion; Large Core Infarct
• Intervention / Treatment: Procedure: Endovascular Therapy

• Study Type: Observational
• Enrollment (Estimated): 518

Contacts and Locations

• Study Contact: Name: Chuanhui Li; Phone Number: 15210439828; Email: lichuanhui@xwh.ccmu.edu.cn

Study Locations

• China
  • Beijing Municipality
    • Beijing, Beijing Municipality, China, 100053
      • Xuanwu Hospital
      • Contact: Chuanhui Li; Phone Number: 15210439828; Email: lichuanhui@xwh.ccmu.edu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Adults (≥18 years) with imaging-confirmed acute vertebrobasilar occlusion and large-core infarction (pc-ASPECTS 0-5) treated within 7 days of symptom onset/last known well at participating centers in China. Patients are identified retrospectively from routine clinical practice and classified according to treatment received: endovascular therapy plus standard medical management versus standard medical management alone.

Description

Inclusion Criteria:

1. Age ≥18 years, men or women.
2. Occlusion (TIMI 0-1) of the basilar artery or intracranial segments of both vertebral arteries (V4) as evidenced by CTA/MRA/DSA.
3. Time from symptom onset (or last known well) to treatment (endovascular therapy or medical therapy) ≤7 days.
4. Patients with large core infarction in the posterior circulation, defined as a posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) score of 0-5 on CT angiography source images or MR with diffusion-weighted imaging or non-contrast CT.

Exclusion Criteria:

1. Subjects with occlusions in both anterior and posterior circulation.
2. CT or MR evidence of hemorrhage (the presence of microbleeds on MRI is allowed).
3. Missing key clinical information (e.g., unavailable baseline NIHSS, unclear symptom onset/last known well time, or missing major treatment information including whether EVT was performed).
4. Baseline NIHSS score <6.
5. Woman of childbearing potential who is known to be pregnant or lactating or who has a positive pregnancy test on admission.
6. Missing follow-up outcomes at 90 days.
7. Any other condition judged by investigators to substantially affect analysis or interpretation.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Endovascular Therapy	Procedure: Endovascular Therapy; Endovascular therapy performed as part of routine clinical care for acute basilar artery occlusion, including mechanical thrombectomy with stent retriever and/or aspiration. Rescue angioplasty and/or intracranial stenting may be used at the operator's discretion. Peri-procedural management and concomitant medical therapy follow local standard practice.
Best Medical Treatment Alone

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of Patients Achieving mRS 0-3 at 90 Days	The modified Rankin scale (range, 0 [no symptoms] to 6 [death]). Higher scores mean a worse outcome.	90 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Ordinal Shift analysis of mRS at 90 days	The modified Rankin scale (range, 0 [no symptoms] to 6 [death])	90 days
Proportion of Patients Achieving mRS 0-3 at 1 year	The modified Rankin scale (range, 0 [no symptoms] to 6 [death]). Higher scores mean a worse outcome.	1 year
Rate of All-Cause Mortality at 90 Days	Death from any cause within 90 days.	90 days
Rate of Symptomatic Intracranial Hemorrhage		24 (-2/+12) hours

Collaborators and Investigators

• Sponsor: Xuanwu Hospital, Beijing

Study record dates

Study Major Dates

• Study Start (Estimated): January 31, 2026
• Primary Completion (Estimated): October 31, 2026
• Study Completion (Estimated): October 31, 2026

Study Registration Dates

• First Submitted: January 7, 2026
• First Submitted That Met QC Criteria: January 7, 2026
• First Posted (Estimated): January 16, 2026

Study Record Updates

• Last Update Posted (Actual): January 20, 2026
• Last Update Submitted That Met QC Criteria: January 15, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Stroke; Ischemic Stroke
• Other Study ID Numbers: BAOCHE-LC

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: The study is proceeding.